Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T00:16:09.906Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychiatric Implications of Endorphin Research

Published online by Cambridge University Press:  29 January 2018

Angus V. P. Mackay
Get access Rights & Permissions [Opens in a new window]

Extract

The revelation that opium-like substances are constitutional body elements is surely one of the major biological advances of the decade. The notion that the brain contains an inbuilt supply of opioid chemicals has been particularly seductive to the psychiatrist. It seems to offer a key to understanding, and therefore manipulating, the cerebral substrates for somatic pain, drug addiction and psychic discomfort. At a time when research effort in this area is increasing logarithmically, I present here a selective and personal view of certain aspects of endorphin research which have been claimed to be psychiatrically relevant. For detailed accounts of the background and breadth of endorphin research the reader is directed to other more extensive recent reviews (Kosterlitz and Hughes, 1977; Guillemin, 1978; Snyder, 1978; Watson et al, 1979; Hughes, 1979). The term endorphin will be used in the generic sense to include the specific Endorphins (such as β-Endorphin) and the enkephalins (Leu- and Met-)—see figure.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 135 , Issue 5 , November 1979 , pp. 470 - 473
Copyright
Copyright © Royal College of Psychiatrists, 1979 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Belluzzi, J. D. & Stein, L. (1977) Enkephalin may mediate euphoria and drive-reduction reward. Nature, 266, 556–8.CrossRefGoogle ScholarPubMed
Bloom, F., Segal, D., Ling, N. & Guillemin, R. (1976) Endorphins: profound behavioural effects in rats suggest new aetiological factors in mental illness. Science, 194, 630–2.CrossRefGoogle ScholarPubMed
Broekkamp, C. L. E., Phillips, A. G. & Cools, A. R. (1979) Stimulant effects of enkephalin microinjection into the dopaminergic A. 10 area. Nature, 278, 560–2.CrossRefGoogle Scholar
Carlsson, E. T. & Simpson, M. M. (1963) Opium as a tranquillizer. American Journal of Psychiatry, 120, 112–17.CrossRefGoogle Scholar
Cox, B. M., Ross, M., Goldstein, A. & Palmour, R. M. (1979) Pharmacological and immunological characterization of the Leu5 analogue of human β-Endorphin. Brain Research, 165, 311–19.CrossRefGoogle ScholarPubMed
Davis, G. C., Bunney, W. E., De Fraites, E. G., Kleinman, J. E., van Kammen, D. P., Post, R. M. & Wyatt, R. J. (1977) Intravenous naloxone administration in schizophrenia and affective illness. Science, 197, 74–7.CrossRefGoogle ScholarPubMed
Emrich, H. M., Cording, C., Piree, S., Rolling, A., Serssen, D. V. & Herz, A. (1977) Indication of antipsychotic action of the opiate antagonist naloxone. Pharmakopsychiatry, 10, 265–70.CrossRefGoogle ScholarPubMed
Guillemin, R. (1978) Peptides in the brain: the new endocrinology of the neuron. Science, 202, 390–402.CrossRefGoogle ScholarPubMed
Gunne, L.-M., Lindstrom, L. & Terenius, L. (1977) Naloxone-induced reversal of schizophrenic hallucinations. Journal of Neural Transmission, 40, 13–19.CrossRefGoogle ScholarPubMed
Ho, W. K. K., Wen, H. L., Lam, S. & Ma, L. (1978) The influence of electro-acupuncture on naloxone-induced morphone withdrawal in mice; elevation of brain opiate-like activity. European Journal of Pharmacology, 49, 197–9.CrossRefGoogle Scholar
Hosobuchi, Y., Rossier, J., Bloom, F. & Guillemin, R. (1979) Stimulation of human periaqueductal gray for pain relief increases immunoreactive β-endorphin in ventricular fluid. Science, 203, 279–81.CrossRefGoogle ScholarPubMed
Hughes, J. (1979) Opioid peptides and their relatives. Nature, 278, 394–5.CrossRefGoogle ScholarPubMed
Jacquet, Y. F. & Marks, N. (1976) The C-fragment of β-lipotropin; an endogenous neuroleptic or anti-psychotogen? Science, 194, 632–4.CrossRefGoogle ScholarPubMed
Janowsky, D. S., Segal, D. S., Bloom, F., Abrams, A. & Guillemin, R. (1977) Lack of effect of naloxone on schizophrenic symptoms. American Journal of Psychiatry, 134, 926–97.Google ScholarPubMed
Kastin, A. J., Sandman, C. A., Schally, A. V. & Ehrensing, R. H. (1978) Clinical effects of hypothalamic-pituitary peptides on the central nervous system. In Clinical Neuropharmacology, Vol. 3 (Ed. Klawans, H. L.). New York: Raven Press.Google Scholar
Kline, N. S., Li, C. H., Lehmann, H. E., Lajtha, A., Laski, E. & Cooper, T. (1977) β-endorphin-induced changes in schizophrenic and depressed patients. Archives of General Psychiatry, 34, 1111–13.CrossRefGoogle ScholarPubMed
Kornetsky, C., Episoto, R. U., McLean, S. & Jacobson, J. O. (1979) Intracranial self-stimulation thresholds. A model for the hedonic effects of drugs of abuse. Archives of General Psychiatry, 36, 289–98.CrossRefGoogle Scholar
Kosterlitz, H. W. & Hughes, J. (1977) Peptides with morphine-like action in the brain. British Journal of Psychiatry, 130, 298–304.CrossRefGoogle ScholarPubMed
Kurland, A. A., McCabe, O. L., Hanlon, T. D. & Sullivan, D. (1977) The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride. American Journal of Psychiatry, 134, 1408–10.Google ScholarPubMed
Levine, J. D., Gordon, J. C. & Fields, H. L. (1978) The mechanism of placebo analgesia. Lancet, ii, 654–7.Google Scholar
Lewis, R. V., Gerber, L. D., Stein, S., Stephen, R. L., Grosser, B. I., Velick, S. F. & Udenfriend, S. (1979) On βH-Leu5-endorphin and schizophrenia. Archives of General Psychiatry, 36, 237–9.CrossRefGoogle ScholarPubMed
Lord, J. A. H., Waterfield, A. A., Hughes, J. & Kosterlitz, H. W. (1977) Endogenous opioid peptides: multiple agonists and receptors. Nature, 267, 495–9.CrossRefGoogle ScholarPubMed
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E. & Gilbert, P. E. (1976) The effects of morphine- and naxolone-like drugs in the nondependent and morphine-dependent chronic spinal dog. Journal of Pharmacology and Experimental Therapeutics, 197, 517–32.Google ScholarPubMed
Mavrojannis, M. (1903) L'action cataleptique de la morphine chez les rats. Contribution a la théorie toxique de la catalepsie. Comptes Rendus de la Société de Biologie, 55, 1092.Google Scholar
Mielke, D. H. & Gallant, D. M. (1977) An oral opiate antagonist in chronic schizophrenia: a pilot study. American Journal of Psychiatry, 134, 1430–1.Google ScholarPubMed
Palmour, R. M., Ervin, F. R. & Wagemaker, H. (1977) Characterization of a peptide derived from the serum of psychiatric patients. Abstracts of the Society of Neurosciences, 7, 32.Google Scholar
Port, F. K., Kroll, P. D. & Swartz, R. D. (1978) The effect of haemodialysis on schizophrenia: a survey of patients with renal failure. American Journal of Psychiatry, 135, 743–4.Google ScholarPubMed
van Ree, J. M., Witter, A. & Leysen, J. E. (1978) Interaction of des-tyrosine-γ-endorphin (DT γ E, β-LPH62H77) with neuroleptic binding sites in various areas of rat brain. European Journal of Pharmacology, 52, 411–13.CrossRefGoogle Scholar
Simpson, G. M., Branchey, M. H. & Lee, J. H. (1977) A trial of naltrexone in chronic schizophrenia. Current Therapeutic Research, 22, 909–13.Google Scholar
Smith, G. M. & Beecher, H. K. (1962) Subjective effects of heroin and morphine in normal subjects. Journal of Pharmacology and Experimental Therapeutics, 136, 47–52.Google ScholarPubMed
Snyder, S. H. (1978) The opiate receptor and morphine-like peptides in the brain. American Journal of Psychiatry, 135, 645–52.Google ScholarPubMed
Terenius, L. (1977) Opioid peptides and opiates differ in receptor selectivity. Psychoneuroendocrinology, 2, 53–8.CrossRefGoogle ScholarPubMed
Terenius, L., Wahlstrom, A., Lindstrom, L. & Widerlov, E. (1976) Increased CSF levels of endorphins in chronic psychosis. Neurosciences Letters, 3, 157–62.CrossRefGoogle ScholarPubMed
Verhoeven, W. M. A., van Praag, H. M., van Ree, J. M. & de Wied, D. (1979) Improvement of schizophrenic patients treated with [Des-Tyr']-γ-endorphin (DT γ E). Archives of General Psychiatry, 36, 294–8.CrossRefGoogle Scholar
Volavka, J., Mallya, A., Baig, S. & Perez-Cruet, J. (1977) Nalaxone in chronic schizophrenia. Science, 196, 1227–8.CrossRefGoogle Scholar
Wagemaker, H. & Cade, R. (1977) The use of haemodialysis in chronic schizophrenia. American Journal of Psychiatry, 134, 684–5.Google ScholarPubMed
Waterfield, A. A., Smokcum, R. W., Hughes, J., Kosterlitz, H. W. & Henderson, G. (1977) In vitro pharmacology of the opioid peptides, enkephalins and endorphins. European Journal of Pharmacology, 43, 107–16.CrossRefGoogle ScholarPubMed
Watson, S. J., Akil, H., Berger, P. A. & Barchas, J. D. (1979) Some observations on the opiate peptides and schizophrenia. Archives of General Psychiatry, 36, 35–41.CrossRefGoogle ScholarPubMed
Watson, S. J., Berger, P. A., Akil, H., Mills, M. J. & Barchas, J. D. (1978) Effects of naloxone in schizophrenia; reduction in hallucinations in a subpopulation of subjects. Science, 201, 73–6.CrossRefGoogle Scholar
de Wied, D., Bohus, B., van Ree, J. M., Kovacs, G. L. & Greven, H. M. (1978) Neuroleptic-like activity of [Des-Tyr']-γ-endorphin in rats. Lancet, i, 1046.CrossRefGoogle Scholar
Wikler, A. (1952) Opiates and opiate antagonists; a review of their mechanisms of action in relation to clinical problems. Public Health Monograph, No. 52. U.S. Department of Health, Education and Welfare.Google Scholar
Wikler, A. & Rasor, R. W. (1953) Psychiatric aspects of drug addiction. American Journal of Medicine, May, 566–70.CrossRefGoogle Scholar
Wikler, A., Pescor, M. J., Kalbaugh, E. P. & Angelucci, R. J. (1951) Effects of frontal lobotomy on the morphine-abstinence syndrome in man. Archives of Neurology and Psychiatry, 67, 510–21.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.